Imunon (IMNN) AGM 2026 summary

Opening remarks and agenda

• The meeting was conducted virtually, with participation limited to shareholders of record as of April 17, 2026.

• The agenda was distributed to all participants, and time was allocated for questions at the end.

• Forward-looking statements were noted, with associated risks detailed in SEC filings.

Board and executive committee updates

• Directors and executive officers were introduced, including the CEO, CFO, and independent public accountants.

• Gratitude was expressed for the board's independence and fiduciary commitment.

Financial performance review

• Multiple financings were executed, including a May 2025 private placement ($3.25M), a December 2025 direct offering ($7M), and up to $10M from a June 2026 flexible financing.

• Financial strategy focused on supporting clinical milestones and extending cash runway.